Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pneumococcal conjugate vaccines in the elderly: role of carrier-specific T cells
2014-000260-17Phase 4Completed
- Sponsor
- University of Innsbruck
- Start
- Jan 2014
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4 trial of Prevnar 13 and acellular pertussis vaccine in pneumococcal disease, diphtheria, Tetanus and 1 more (2 arms), sponsored by University of Innsbruck. Primary endpoint: Vaccine-induced immune response at 6 weeks. Started Jan 2014; status: completed.
02
Drugs
Prevnar 13acellular pertussis vaccine
03
Conditions
pneumococcal diseasediphtheriaTetanuspertussis
Beyond the preview
Go deeper on 2014-000260-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000260-17.